相似文献
1
Single-dose pharmacokinetics of porcine factor VIII (Hyate C).
Thromb Haemost. 2002 Feb;87(2):352-3.
2
Determination of pharmacokinetics of replacement factor VIII.
Semin Hematol. 1990 Apr;27(2 Suppl 2):8-10.
3
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
Haemophilia. 2012 Sep;18(5):798-804. doi: 10.1111/j.1365-2516.2012.02789.x. Epub 2012 Apr 19.
4
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
Thromb Haemost. 2000 Jan;83(1):65-9.
5
Extended half-life factor VIII for immune tolerance induction in haemophilia.
Haemophilia. 2016 Nov;22(6):e552-e554. doi: 10.1111/hae.13064. Epub 2016 Sep 19.
6
[Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
Acta Haematol Pol. 1996;27(1):27-31.
7
Porcine factor VIIIC in the management of patients with factor VIII inhibitors.
Transfus Med Rev. 1991 Oct;5(4):293-9. doi: 10.1016/s0887-7963(91)70224-1.
8
The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
Semin Hematol. 1993 Apr;30(2 Suppl 1):22-7.
9
Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma.
Haemophilia. 2017 Sep;23(5):e453-e456. doi: 10.1111/hae.13247. Epub 2017 Jun 29.
10
The use of porcine factor VIII in Japan.
Semin Hematol. 1994 Apr;31(2 Suppl 4):26-8.
Zotero 插件